Loxo Oncology (Loxo Oncology) NonCurrent Deferred Liabilities : $106.2 Mil (As of Sep. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Loxo Oncology NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Loxo Oncology's non-current deferred liabilities for the quarter that ended in Sep. 2018 was $106.2 Mil.

Loxo Oncology NonCurrent Deferred Liabilities Historical Data

The historical data trend for Loxo Oncology's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Loxo Oncology NonCurrent Deferred Liabilities Chart

Loxo Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

NonCurrent Deferred Liabilities

183.66

Loxo Oncology Quarterly Data
	Sep13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															-	183.66	159.69	138.48	106.24

Loxo Oncology NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Loxo Oncology's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Loxo Oncology (Loxo Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Loxo Oncology Inc (NAS:LOXO) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.loxooncology.com

Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Executives

Jennifer Burstein	officer: Senior VP of Finance	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Keith T. Flaherty	director	55 FRUIT STREET, YAWKEY 9E, BOSTON MA 02114
Lori Anne Kunkel	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Joshua H. Bilenker	director, officer: President & CEO	C/O LOXO ONCOLOGY, INC., ONE LANDMARK SQUARE, SUITE 1122, STAMFORD CT 06901
Steve Elms	director, 10 percent owner	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Alan Fuhrman	director	C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Andrew N Schiff	10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Dennis J Purcell	10 percent owner	AUXILIUM PHARMACEUTICALS, INC., 160 WEST GERMANTOWN PIKE, NORRISTOWN PA 19401
Aisling Capital Iii Lp	10 percent owner	888 Seventh Avenue, 30th Fl, New York NY 10106
Aisling Capital Partners Iii Lp	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Aisling Capital Partners Iii Llc	10 percent owner	AISLING CAPITAL LLC, 888 SEVENTH AVENUE 30TH FLOOR, NEW YORK NY 10106
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp V Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Samuel D Isaly	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022